Liquidia Corporation (LQDA)

Market Cap	459.85M
Revenue (ttm)	13.79M
Net Income (ttm)	-46.05M
Shares Out	64.50M
EPS (ttm)	-0.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	625,229
Open	7.13
Previous Close	7.01
Day's Range	7.06 - 7.37
52-Week Range	3.26 - 8.79
Beta	0.13
Analysts	Buy
Price Target	13.41 (+88.08%)
Earnings Date	Mar 16, 2023

About LQDA

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 26, 2018
• Employees: 52
• Stock Exchange: NASDAQ
• Ticker Symbol: LQDA

Financial Performance

In 2021, Liquidia's revenue was $12.85 million, an increase of 1637.81% compared to the previous year's $739,628. Losses were -$34.58 million, -42.14% less than in 2020.

Analyst Forecast

According to 13 analysts, the average rating for LQDA stock is "Buy." The 12-month stock price forecast is $13.41, which is an increase of 88.08% from the latest price.

Price Target

$13.41

(88.08% upside)

Analyst Consensus: Buy